

La Renon

THE TRIPLE IMPACT



LAFORMIN

Glimepiride 1 mg / 2 mg + Pioglitazone 15 mg
+ Metformin (SR) 500 mg Tablets

GP-1

GP-2

LAFORMIN

GP-1
GP-2

Glimepiride 1 mg / 2 mg + Pioglitazone 15 mg
+ Metformin (SR) 500 mg Tablets



Description

Laformin GP-1 and GP-2 is a Triple drug Combination consists of Glimepiride, Pioglitazone and Metformin Sustained Release for the treatment and management of type-2 diabetes mellitus in adults.

Indication

LAFORMIN GP-1/GP-2 Tablets are indicated once daily, as an adjunct to diet and exercise, to lower blood glucose. It is indicated as second-line therapy when diet, exercise, and the single agents or dual therapy do not result in adequate glycemic control in patients with type-2 diabetes.

Mechanism of Action

Glimepiride

The primary mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells.

Metformin

Metformin improves glucose tolerance in patients with type-2 diabetes (NIDDM), lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.

Pioglitazone

It selectively stimulates the nuclear receptor peroxisome proliferator activated receptor gamma (PPAR- γ). It modulates the transcription of the insulin-sensitive genes involved in the control of glucose and lipid metabolism in the muscle, adipose tissue, and the liver. As a result, pioglitazone reduces insulin resistance in the liver and peripheral tissues; increases the expense of insulin-dependent glucose; decreases withdrawal of glucose from the liver; reduces quantity of glucose, insulin and glycated hemoglobin in the bloodstream.

Dosage and Administration

- ◆ LAFORMIN GP1/GP 2 should be given once daily with the first meal of the day.
- ◆ There is no fixed dose regimen for the management of hyperglycemia in patients with type 2 diabetes with this combination or any other pharmacological agent.
- ◆ Dose should be individualized on the basis of both effectiveness and tolerance, while no exceeding the maximum recommended daily dose.
- ◆ The maximum recommended daily dose of this combination in adults should not exceed 3 tablets.

La Renon Healthcare Private Limited

207-208 Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,
S.G. Highway, Ahmedabad-380015, Gujarat, India.
Phone: + 91-79-6616-8998, 2693-6656 | Fax: +91-79-6616-8998
E-mail: info@larenon.com | Web: www.larenon.com

© 2025 All rights reserved, La Renon Healthcare Private Limited



Scan QR for more
Prescribing Information

1 I am:	
2 Call me on:	
3 Mail me at:	